CRS

ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Retrieved on: 
Lunedì, Maggio 6, 2024
PSMA, FDA, Net, University, Part, DLBCL, EDT, City, CRS, Safety, PIN, University of Miami, Pancreatic cancer, Infrared spectroscopy correlation table, Research, Hematology, Insurance, PR, MD, Growth, ICU, Rituximab, Follicular lymphoma, ADC, Patient, Therapeutic index, Sarcoma, S&M, Diffuse large B-cell lymphoma, NHL, Cytokine release syndrome, Marketing, IIT, Advertising, Therapy, NSCLC, Spacecraft, AXL, Lung cancer, Pharmaceutical industry

Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.

Key Points: 
  • Sequential quarter-over-quarter growth in the first quarter of 2024 continued, with sales volume increasing in both community and academic settings.
  • Net product revenues were $17.8 million for the first quarter 2024, compared to $19.0 million for the first quarter 2023.
  • R&D expenses were $25.7 million for the first quarter 2024, compared to $38.4 million for the first quarter 2023.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss first quarter 2024 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Carnegie Investment Counsel Expands Advisor Opportunities in Key Markets

Retrieved on: 
Mercoledì, Maggio 8, 2024
CRS, Fidelity, Partnership, RIA, Form, Multimedia, Marketing, Ball, Financial adviser

Key highlights for prospective advisors include:

Key Points: 
  • Key highlights for prospective advisors include:
    Comprehensive Support: Carnegie Investment Counsel offers dedicated marketing, business development, and back-office support, enabling advisors to focus on client relationships.
  • Ownership Potential: Carnegie Investment Counsel offers competitive compensation and benefits, including equity participation, fostering long-term career growth and ownership opportunities.
  • For more information about advisor opportunities at Carnegie Investment Counsel, please contact Gary Wagner at [email protected] or (216) 367-4106.
  • Carnegie Investment Counsel ("Carnegie") has been serving investors since 1974, founded by Prescott, Ball & Turben.

AHN, Innovation Works AlphaLab Health Joint Venture Receives $10 Million Grant to Create Revolving Investment Fund

Retrieved on: 
Martedì, Maggio 7, 2024
Investment, CRS, Community health, IW, Infection, Cytokine release syndrome, Machine learning, Immunotherapy, Innovation, MD, Partnership, AHN, Allegheny Health Network, Obstructive sleep apnea, Immune system, OSA

BELLEVUE, Pa., May 7, 2024 /PRNewswire-PRWeb/ -- AlphaLab Health, an accelerator program developed by Innovation Works and Allegheny Health Network for life-sciences startups in the Pittsburgh region, has received a $10 million grant from an anonymous donor to create an evergreen fund.

Key Points: 
  • The grant establishes the AlphaLab Health Revolving Investment Fund, which will support startups in the accelerator program.
  • The investment returns generated by the fund will create a permanent, self-sustaining source of revenue that will be reinvested into future AlphaLab startups.
  • AlphaLab Health is based at Allegheny Health Network (AHN) Suburban, the former Bellevue acute-care hospital that has been reinvented as a community innovation hub.
  • "This significant grant will propel AlphaLab Health into the next decade of health care innovation and beyond," said Mitch Beckman, Chief Development Officer at Highmark Health, parent company of AHN.

Sonata Software: International Services Dollar revenue for FY'24 of 323.6 Mn grew 34.3% YoY; Domestic business delivered Gross contribution for FY'24 of 260.4 Cr 18.6% YoY growth in INR; The Board recommends a final dividend of ₹ 4.40 per share (FY'24 tot

Retrieved on: 
Martedì, Maggio 7, 2024
USD, Quarter, CRS, Yoy, Health care, MD, TMT, Digital, Microsoft, PAT, BFSI, TTH, Q4, Pension fund

EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%

Key Points: 
  • EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%
    PAT for Q4'24 stood at ₹ 70.3 Crores; QoQ de-growth of 18.2%.
  • Revenues for FY'24 at ₹ 5950.5 crores; YoY growth of 7.4%
    Gross contribution for Q4'24 at ₹ 64.8 Crs de-grew by 9.1% QoQ.
  • Gross contribution for FY'24 at ₹ 260.4 Crs grew by 18.6% YoY
    EBITDA for Q4'24 at ₹ 56.2 crores; QoQ de-growth of 4.5%.
  • EBITDA for FY'24 at ₹ 228.3 crores; YoY growth of 16.0%
    PAT for Q4'24 at ₹ 40.1 crores; QoQ de-growth of 5.9%.

Sonata Software: International Services Dollar revenue for FY'24 of 323.6 Mn grew 34.3% YoY; Domestic business delivered Gross contribution for FY'24 of 260.4 Cr 18.6% YoY growth in INR; The Board recommends a final dividend of ₹ 4.40 per share (FY'24 tot

Retrieved on: 
Martedì, Maggio 7, 2024
USD, Quarter, CRS, Yoy, Health care, MD, TMT, Digital, Microsoft, PAT, BFSI, TTH, Q4, Pension fund

EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%

Key Points: 
  • EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%
    PAT for Q4'24 stood at ₹ 70.3 Crores; QoQ de-growth of 18.2%.
  • Revenues for FY'24 at ₹ 5950.5 crores; YoY growth of 7.4%
    Gross contribution for Q4'24 at ₹ 64.8 Crs de-grew by 9.1% QoQ.
  • Gross contribution for FY'24 at ₹ 260.4 Crs grew by 18.6% YoY
    EBITDA for Q4'24 at ₹ 56.2 crores; QoQ de-growth of 4.5%.
  • EBITDA for FY'24 at ₹ 228.3 crores; YoY growth of 16.0%
    PAT for Q4'24 at ₹ 40.1 crores; QoQ de-growth of 5.9%.

Sabre and Taiba Investments Forge Strategic Partnership to Enhance Hotel Distribution in Saudi Arabia

Retrieved on: 
Martedì, Maggio 7, 2024
Sabre Corporation, CRS, Investment, Sabre, Partnership, Senior, Acquisition, Travel, SABR, Growth

This collaboration will see the adoption of Sabre Hospitality's SynXis platform across multiple hotel brands within Taiba Investments' portfolio, including Makarem and Nur.

Key Points: 
  • This collaboration will see the adoption of Sabre Hospitality's SynXis platform across multiple hotel brands within Taiba Investments' portfolio, including Makarem and Nur.
  • This partnership underscores both companies' commitment to leveraging innovative technology to drive growth and deliver exceptional guest experiences.
  • "Our partnership with Sabre is a testament to Taiba Investments' strategic focus on redefining Saudi hospitality services by adopting innovative solutions that enhance our operational capabilities and enrich our guests' experiences," said Hassan Ahdab, Chief Hospitality Operations Officer - Taiba Investments Company.
  • The agreement between Sabre and Taiba Investments marks a significant step forward in the use of technology to enhance the hotel guest experience in Saudi Arabia.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
Venerdì, Maggio 3, 2024
FDA, Congress, Cancer, Urinary tract infection, Urinary diversion, Safety, Carcinoma, Survival, Johnson & Johnson, Immunotherapy, CRS, Abstract, Cohort, BCG, Disease, Bladder cancer, Dysuria, Patient, Metastasis, Medicine, NMIBC, AUA, Biopsy, BTD, Urination, Interim, Food and Drug Administration, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
Mercoledì, Maggio 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

Space-Made Fibers and Novel Biotech Among Research Returning to Earth After Successful Space Station Mission

Retrieved on: 
Martedì, Aprile 30, 2024
Janus, SpaceX, Drug, SPACE, University, ISS, Seed, International Space Station, CRS, Research, Oklahoma State University–Stillwater, NASA, United States national laboratories, Commercial Resupply Services, Plant, B cell, Engineering, Therapy, Mathematics, Arthritis, Patient, ISS National Lab, ZBLAN, Health, Cartilage, Student, SpaceX Dragon, Growth, Choctaw Nation of Oklahoma, Communications satellite

KENNEDY SPACE CENTER, Fla., April 30, 2024 /PRNewswire/ -- Research on a novel vision loss therapy and space-manufactured optical fibers were among the nearly 565 pounds of science and technology payloads sponsored by the International Space Station (ISS) National Laboratory that splashed down off the Florida coast Tuesday morning as NASA concluded SpaceX's 30th Commercial Resupply Services (CRS) mission.

Key Points: 
  • Encapsulate leveraged the microgravity environment of the space station to validate an automated tumor-on-a-chip system that grows patient-derived cancer cells to test chemotherapy drugs.
  • Using powdered protein could significantly reduce the mass of materials sent to space for manufacturing, allowing increased production at a lower cost.
  • From mid-February to mid-March, the company manufactured a total of more than seven miles (11.9 km) of optical fiber on station.
  • These are just a few of the investigations returning to Earth in the SpaceX Dragon capsule on this mission.

Truecanhelp Unveils New CRS Score Calculator to Enhance the Canadian Immigration Process

Retrieved on: 
Venerdì, Aprile 26, 2024
Express Entry, Education, CRS, PNP, Online shopping

Innovative Tool Designed to Help Prospective Immigrants Assess Their Eligibility for Express Entry

Key Points: 
  • The CRS Score Calculator by Truecanhelp is developed to provide immediate feedback on an applicant's Comprehensive Ranking System (CRS) score, considering various factors such as age, education, language proficiency, work experience, and eligibility under programs like the Provincial Nominee Program (PNP) .
  • With the introduction of the CRS Score Calculator, applicants can quickly determine their CRS scores, allowing them to understand better their standing in the pool of candidates for immigration.
  • The CRS Score Calculator not only enhances the user experience but also reflects Truecanhelp's dedication to fostering a supportive and efficient immigration process.
  • For more information about the CRS Score Calculator and to explore Truecanhelp's comprehensive range of immigration services, please visit Truecanhelp's website .